Hans H Maurer

Summary

Country: Germany

Publications

  1. Michely J, Helfer A, Brandt S, Meyer M, Maurer H. Metabolism of the new psychoactive substances N,N-diallyltryptamine (DALT) and 5-methoxy-DALT and their detectability in urine by GC-MS, LC-MSn, and LC-HR-MS-MS. Anal Bioanal Chem. 2015;407:7831-42 pubmed publisher
    ..The most abundant targets were a ring hydroxy metabolite of DALT, the N,O-bis-dealkyl metabolite of 5-MeO-DALT, and their glucuronides. GC-MS enabled screening of DALT by use of its main metabolites only. ..
  2. Helfer A, Michely J, Weber A, Meyer M, Maurer H. Orbitrap technology for comprehensive metabolite-based liquid chromatographic-high resolution-tandem mass spectrometric urine drug screening - exemplified for cardiovascular drugs. Anal Chim Acta. 2015;891:221-33 pubmed publisher
    ..The novel LC-HR-MS/MS method allowed fast, simple, and robust urine screening, particularly for cardiovascular drugs showing the usefulness of Orbitrap technology for drug testing. ..
  3. Caspar A, Meyer M, Westphal F, Weber A, Maurer H. Nano liquid chromatography-high-resolution mass spectrometry for the identification of metabolites of the two new psychoactive substances N-(ortho-methoxybenzyl)-3,4-dimethoxyamphetamine and N-(ortho-methoxybenzyl)-4-methylmethamphetamine. Talanta. 2018;188:111-123 pubmed publisher
    ..Suggested targets for urine screening procedures were O-demethyl- and O,O-bis-demethyl-3,4-DMA-NBOMe and their glucuronides and carboxy-4-MMA-NBOMe and its glucuronide and N-demethyl-carboxy-4-MMA-NBOMe. ..
  4. Dinger J, Meyer M, Maurer H. Development of an in vitro cytochrome P450 cocktail inhibition assay for assessing the inhibition risk of drugs of abuse. Toxicol Lett. 2014;230:28-35 pubmed publisher
    ..In conclusion, the new inhibition cocktail assay was reproducible and applicable for testing the inhibition potential of drugs of abuse as exemplified for 2,5-dimethoxy-4-iodo-amfetamine (DOI). ..
  5. Dinger J, Meyer M, Maurer H. In vitro cytochrome P450 inhibition potential of methylenedioxy-derived designer drugs studied with a two-cocktail approach. Arch Toxicol. 2016;90:305-18 pubmed publisher
    ..These results showed that the CYP inhibition by MDD might be clinically relevant, but further studies are needed for final conclusions. ..
  6. Wink C, Meyer G, Meyer M, Maurer H. Toxicokinetics of lefetamine and derived diphenylethylamine designer drugs-Contribution of human cytochrome P450 isozymes to their main phase I metabolic steps. Toxicol Lett. 2015;238:39-44 pubmed publisher
    ..Due to the involvement of at least four enzymes in the initial metabolic steps, the risk of CYP-related drug-drug or drug-food interactions should be low. ..
  7. Wagmann L, Maurer H. Bioanalytical Methods for New Psychoactive Substances. Handb Exp Pharmacol. 2018;: pubmed publisher
    ..PubMed-listed and English-written original research papers and review articles published online between 01 October 2012 and 30 September 2017 were considered. ..
  8. Dinger J, Woods C, Brandt S, Meyer M, Maurer H. Cytochrome P450 inhibition potential of new psychoactive substances of the tryptamine class. Toxicol Lett. 2016;241:82-94 pubmed publisher
    ..Nineteen compounds showed inhibition of CYP2E1 and 18 of CYP3A activity, respectively. These results showed that the CYP inhibition by TDNPS might be clinically relevant, but clinical studies are needed to explore this further. ..
  9. Wink C, Michely J, Jacobsen Bauer A, Zapp J, Maurer H. Diphenidine, a new psychoactive substance: metabolic fate elucidated with rat urine and human liver preparations and detectability in urine using GC-MS, LC-MSn , and LC-HR-MSn. Drug Test Anal. 2016;8:1005-1014 pubmed publisher
    ..After application of a common users' dose, diphenidine metabolites could be detected in rat urine by the authors' GC-MS as well as LC-MSn SUSA. Copyright © 2016 John Wiley & Sons, Ltd. ..

More Information

Publications22

  1. Wagmann L, Meyer M, Maurer H. What is the contribution of human FMO3 in the N-oxygenation of selected therapeutic drugs and drugs of abuse?. Toxicol Lett. 2016;258:55-70 pubmed publisher
    ..The successful application of a modified RAF approach including FMO3 proved the importance of FMO3 in the N-oxygenation of DOAs in human metabolism. ..
  2. Caspar A, Meyer M, Maurer H. Human cytochrome P450 kinetic studies on six N-2-methoxybenzyl (NBOMe)-derived new psychoactive substances using the substrate depletion approach. Toxicol Lett. 2018;285:1-8 pubmed publisher
    ..However, in cases where substances with high contributions from polymorphically expressed CYP2C19 and CYP2D6 are encountered, inter-individual variations in metabolism and excretion cannot be excluded. ..
  3. Richter L, Kaminski Y, Noor F, Meyer M, Maurer H. Metabolic fate of desomorphine elucidated using rat urine, pooled human liver preparations, and human hepatocyte cultures as well as its detectability using standard urine screening approaches. Anal Bioanal Chem. 2016;408:6283-94 pubmed publisher
    ..Finally, desomorphine (crocodile) consumption should be detectable by all standard urine screening approaches mainly via the parent compound and/or its glucuronide assuming similar kinetics in rats and humans. ..
  4. Helfer A, Michely J, Weber A, Meyer M, Maurer H. LC-HR-MS/MS standard urine screening approach: Pros and cons of automated on-line extraction by turbulent flow chromatography versus dilute-and-shoot and comparison with established urine precipitation. J Chromatogr B Analyt Technol Biomed Life Sci. 2017;1043:138-149 pubmed publisher
  5. Maurer H, Meyer M. High-resolution mass spectrometry in toxicology: current status and future perspectives. Arch Toxicol. 2016;90:2161-2172 pubmed publisher
    ..Finally, a discussion on advantages as well as limitations and future perspectives of these methods is included. ..
  6. Michely J, Brandt S, Meyer M, Maurer H. Biotransformation and detectability of the new psychoactive substances N,N-diallyltryptamine (DALT) derivatives 5-fluoro-DALT, 7-methyl-DALT, and 5,6-methylenedioxy-DALT in urine using GC-MS, LC-MSn, and LC-HR-MS/MS. Anal Bioanal Chem. 2017;409:1681-1695 pubmed publisher
  7. Caspar A, Brandt S, Stoever A, Meyer M, Maurer H. Metabolic fate and detectability of the new psychoactive substances 2-(4-bromo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25B-NBOMe) and 2-(4-chloro-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25C-NBOMe) in human and . J Pharm Biomed Anal. 2017;134:158-169 pubmed publisher
    ..The presented study demonstrated that 25B-NBOMe and 25C-NBOMe were extensively metabolized and detectable by both LC-based SUSAs. ..
  8. Helfer A, Michely J, Weber A, Meyer M, Maurer H. Liquid chromatography-high resolution-tandem mass spectrometry using Orbitrap technology for comprehensive screening to detect drugs and their metabolites in blood plasma. Anal Chim Acta. 2017;965:83-95 pubmed publisher
    ..Applicability studies showed that the developed method provided fast, simple, and robust screening and identification of a broad range of drugs within therapeutic ranges. ..
  9. Caspar A, Westphal F, Meyer M, Maurer H. LC-high resolution-MS/MS for identification of 69 metabolites of the new psychoactive substance 1-(4-ethylphenyl-)-N-[(2-methoxyphenyl)methyl] propane-2-amine (4-EA-NBOMe) in rat urine and human liver S9 incubates and comparison of its screening powe. Anal Bioanal Chem. 2018;410:897-912 pubmed publisher
    ..The main targets for both LC-MS screenings should be the phenylacetic acid derivative, the mandelic acid derivative both with and without additional O-demethylation, and, for GC-MS, the hydroxy metabolite after conjugate cleavage. ..
  10. Maurer H. Analytical toxicology. EXS. 2010;100:317-37 pubmed
    ..The importance of quality control and possibilities and limitations of interpretation of the analytical result are also discussed. ..
  11. Maurer H. How can analytical diagnostics in clinical toxicology be successfully performed today?. Ther Drug Monit. 2012;34:561-4 pubmed publisher
    ..Quality control aspects and strategies for competent interpretation of the analytical result in correlation with the clinical signs presented by the patient are discussed. ..
  12. Maurer H. Chemistry, pharmacology, and metabolism of emerging drugs of abuse. Ther Drug Monit. 2010;32:544-9 pubmed publisher
    ..They have gained popularity and notoriety as rave drugs. The metabolic pathways, the involvement of cytochrome P450 isoenzymes in the main pathways, and their roles in hepatic clearance are also summarized...
  13. Michely J, Meyer M, Maurer H. Dried urine spots - A novel sampling technique for comprehensive LC-MSn drug screening. Anal Chim Acta. 2017;982:112-121 pubmed publisher
    ..In conclusion, DUS might be an alternative sampling technique for comprehensive drug testing or adherence monitoring. ..